Back to Search
Start Over
Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
- Source :
-
PloS one [PLoS One] 2017 Jan 26; Vol. 12 (1), pp. e0170825. Date of Electronic Publication: 2017 Jan 26 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- Fingolimod, the first oral, disease-modifying therapy for MS, has been recently proposed to modulate glutamate transmission in the central nervous system (CNS) of mice suffering from Experimental Autoimmune Encephalomyelitis (EAE) and in MS patients. Our study aims at investigating whether oral fingolimod recovers presynaptic defects that occur at different stages of disease in the CNS of EAE mice. In vivo prophylactic (0.3 mg/kg for 14 days, from the 7th day post immunization, d.p.i, the drug dissolved in the drinking water) fingolimod significantly reduced the clinical symptoms and the anxiety-related behaviour in EAE mice. Spinal cord inflammation, demyelination and glial cell activation are markers of EAE progression. These signs were ameliorated following oral fingolimod administration. Glutamate exocytosis was shown to be impaired in cortical and spinal cord terminals isolated from EAE mice at 21 ± 1 d.p.i., while GABA alteration emerged only at the spinal cord level. Prophylactic fingolimod recovered these presynaptic defects, restoring altered glutamate and GABA release efficiency. The beneficial effect occurred in a dose-dependent, region-specific manner, since lower (0.1-0.03 mg/kg) doses restored, although to a different extent, synaptic defects in cortical but not spinal cord terminals. A delayed reduction of glutamate, but not of GABA, exocytosis was observed in hippocampal terminals of EAE mice at 35 d.p.i. Therapeutic (0.3 mg/kg, from 21 d.p.i. for 14 days) fingolimod restored glutamate exocytosis in the cortex and in the hippocampus of EAE mice at 35 ± 1 d.p.i. but not in the spinal cord, where also GABAergic defects remained unmodified. These results improve our knowledge of the molecular events accounting for the beneficial effects elicited by fingolimod in demyelinating disorders.<br />Competing Interests: The authors have declared that no competing interests exist.
- Subjects :
- Administration, Oral
Animals
Cerebral Cortex drug effects
Cerebral Cortex immunology
Cerebral Cortex pathology
Dose-Response Relationship, Drug
Encephalomyelitis, Autoimmune, Experimental immunology
Encephalomyelitis, Autoimmune, Experimental pathology
Exocytosis drug effects
Female
Glutamic Acid metabolism
Glutamic Acid pharmacology
Hippocampus drug effects
Hippocampus immunology
Hippocampus pathology
Mice
Mice, Inbred C57BL
Neuroglia drug effects
Neuroglia immunology
Neuroglia pathology
Organ Specificity
Spinal Cord drug effects
Spinal Cord immunology
Spinal Cord pathology
Synapses immunology
Synapses pathology
gamma-Aminobutyric Acid metabolism
gamma-Aminobutyric Acid pharmacology
Encephalomyelitis, Autoimmune, Experimental drug therapy
Encephalomyelitis, Autoimmune, Experimental prevention & control
Fingolimod Hydrochloride pharmacology
Immunosuppressive Agents pharmacology
Synapses drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 12
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 28125677
- Full Text :
- https://doi.org/10.1371/journal.pone.0170825